PEDIATRICS Vol. 106 No. 2 August 2000, pp. 367-376

AMERICAN ACADEMY OF PEDIATRICS:
Technical Report: Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Polysaccharide Vaccines and Antibiotic Prophylaxis

Committee on Infectious Diseases, 1999-2000

Jon S. Abramson, MD, Chairperson Carol J. Baker, MD Margaret C. Fisher, MD Michael A. Gerber, MD H. Cody Meissner, MD Dennis L. Murray, MD Gary D. Overturf, MD Charles G. Prober, MD Margaret B. Rennels, MD Thomas N. Saari, MD Leonard B. Weiner, MD Richard J. Whitley, MD

Ex-Officio

Georges Peter, MD  Emeritus Red Book Editor Larry K. Pickering, MD  Red Book Editor Noni E. MacDonald, MD  Red Book Associate Editor

Liaisons

Lance Chilton, MD  Pediatric Practice Action Group Richard F. Jacobs, MD  American Thoracic Society Gilles Delage, MD  Canadian Paediatric Society Scott F. Dowell, MD, MPH  Centers for Disease Control and Prevention Walter A. Orenstein, MD  Centers for Disease Control and Prevention Peter A. Patriarca, MD  Food and Drug Administration Martin G. Myers, MD  National Vaccine Program Office

Consultant

Edgar O. Ledbetter, MD

Staff

Joann Kim, MD

Pneumococcal infections are the most common invasive bacterial infections in children in the United States. The incidence of invasive pneumococcal infections peaks in children younger than 2 years, reaching rates of 228/100 000 in children 6 to 12 months old. Children with functional or anatomic asplenia (including sickle cell disease [SCD]) and children with human immunodeficiency virus infection have pneumococcal infection rates 20- to 100-fold higher than those of healthy children during the first 5 years of life. Others at high risk of pneumococcal infections include children with congenital immunodeficiency; chronic cardiopulmonary disease; children receiving immunosuppressive chemotherapy; children with immunosuppressive neoplastic diseases; children with chronic renal insufficiency, including nephrotic syndrome; children with diabetes; and children with cerebrospinal fluid leaks. Children of Native American (American Indian and Alaska Native) or African American descent also have higher rates of invasive pneumococcal disease. Outbreaks of pneumococcal infection have occurred with increased frequency in children attending out-of-home care. Among these children, nasopharyngeal colonization rates of 60% have been observed, along with pneumococci resistant to multiple antibiotics. The administration of antibiotics to children involved in outbreaks of pneumococcal disease has had an inconsistent effect on nasopharyngeal carriage. In contrast, continuous penicillin prophylaxis in children younger than 5 years with SCD has been successful in reducing rates of pneumococcal disease by 84%.

Pneumococcal polysaccharide vaccines have been recommended since 1985 for children older than 2 years who are at high risk of invasive disease, but these vaccines were not recommended for younger children and infants because of poor antibody response before 2 years of age. In contrast, pneumococcal conjugate vaccines (Prevnar) induce proposed protective antibody responses (>.15 µg/mL) in >90% of infants after 3 doses given at 2, 4, and 6 months of age. After priming doses, significant booster responses (ie, immunologic memory) are apparent when additional doses are given at 12 to 15 months of age. In efficacy trials, infant immunization with Prevnar decreased invasive infections by >93% and consolidative pneumonia by 73%, and it was associated with a 7% decrease in otitis media and a 20% decrease in tympanostomy tube placement. Adverse events after the administration of Prevnar have been limited to areas of local swelling or erythema of 1 to 2 cm and some increase in the incidence of postimmunization fever when it is given with other childhood vaccines. Based on data in phase 3 efficacy and safety trials, the US Food and Drug Administration has provided an indication for the use of Prevnar in children younger than 24 months.

This article has been cited by other articles:

				K. A. Poehling, P. G. Szilagyi, C. G. Grijalva, S. W. Martin, B. LaFleur, E. Mitchel, R. D. Barth, J. P. Nuorti, and M. R. Griffin Reduction of Frequent Otitis Media and Pressure-Equalizing Tube Insertions in Children After Introduction of Pneumococcal Conjugate Vaccine Pediatrics, April 1, 2007; 119(4): 707 - 715. [Abstract] [Full Text] [PDF]

				P. L. Lin, M. G. Michaels, M. Green, G. V. Mazariegos, S. A. Webber, K. S. Lawrence, K. Iurlano, and D. P. Greenberg Safety and Immunogenicity of the American Academy of Pediatrics-Recommended Sequential Pneumococcal Conjugate and Polysaccharide Vaccine Schedule in Pediatric Solid Organ Transplant Recipients Pediatrics, July 1, 2005; 116(1): 160 - 167. [Abstract] [Full Text] [PDF]

				M. M. Pettigrew and K. P. Fennie Genomic Subtraction Followed by Dot Blot Screening of Streptococcus pneumoniae Clinical and Carriage Isolates Identifies Genetic Differences Associated with Strains That Cause Otitis Media Infect. Immun., May 1, 2005; 73(5): 2805 - 2811. [Abstract] [Full Text] [PDF]

				B. T. Hu, X. Yu, T. R. Jones, C. Kirch, S. Harris, S. W. Hildreth, D. V. Madore, and S. A. Quataert Approach to Validating an Opsonophagocytic Assay for Streptococcus pneumoniae Clin. Vaccine Immunol., February 1, 2005; 12(2): 287 - 295. [Abstract] [Full Text] [PDF]

				R. R. Ramani, W. N. Hall, M. Boulton, D. R. Johnson, and B.-P. Zhu Impact of PCV7 on Invasive Pneumococcal Disease Among Children Younger Than 5 Years: A Population-Based Study Am J Public Health, June 1, 2004; 94(6): 958 - 959. [Abstract] [Full Text] [PDF]

				R. E. Wilson, L. Krishnamurti, and D. Kamat Management of Sickle Cell Disease in Primary Care Clinical Pediatrics, November 1, 2003; 42(9): 753 - 761. [PDF]

				C. M. Sox, W. O. Cooper, T. D. Koepsell, D. L. DiGiuseppe, and D. A. Christakis Provision of Pneumococcal Prophylaxis for Publicly Insured Children With Sickle Cell Disease JAMA, August 27, 2003; 290(8): 1057 - 1061. [Abstract] [Full Text] [PDF]

				C C Grant, A R Harnden, G Jewell, K Knox, T E Peto, and D W Crook Invasive pneumococcal disease in Oxford, 1985-2001: a retrospective case series Arch. Dis. Child., August 1, 2003; 88(8): 712 - 714. [Abstract] [Full Text] [PDF]

				A. S. Artz, W. B. Ershler, and D. L. Longo Pneumococcal Vaccination and Revaccination of Older Adults Clin. Microbiol. Rev., April 1, 2003; 16(2): 308 - 318. [Abstract] [Full Text] [PDF]

				H. Bauchner and R. E. Besser Promoting the Appropriate Use of Oral Antibiotics: There Is Some Very Good News Pediatrics, March 1, 2003; 111(3): 668 - 670. [Full Text] [PDF]

				S. J. Schaffer, P. G. Szilagyi, L. P. Shone, S. J. Ambrose, M. K. Dunn, R. D. Barth, K. Edwards, G. A. Weinberg, S. Balter, and B. Schwartz Physician Perspectives Regarding Pneumococcal Conjugate Vaccine Pediatrics, December 1, 2002; 110(6): e68 - 68. [Abstract] [Full Text] [PDF]

				T. Q. Tan, E. O. Mason Jr, E. R. Wald, W. J. Barson, G. E. Schutze, J. S. Bradley, L. B. Givner, R. Yogev, K. S. Kim, and S. L. Kaplan Clinical Characteristics of Children With Complicated Pneumonia Caused by Streptococcus pneumoniae Pediatrics, July 1, 2002; 110(1): 1 - 6. [Abstract] [Full Text] [PDF]

				J. Buttery and E R. Moxon Capsulate bacteria and the lung: Childhood respiratory infections Br. Med. Bull., March 1, 2002; 61(1): 63 - 80. [Abstract] [Full Text] [PDF]

				Section on Hematology/Oncology and Committee on Ge Health Supervision for Children with Sickle Cell Disease Pediatrics, March 1, 2002; 109(3): 526 - 535. [Abstract] [Full Text] [PDF]

				J. Abramson Academy monitoring PCV7 shortage AAP News, December 1, 2001; 19(6): 239 - 239. [Full Text] [PDF]

				E. R. Alpern, E. A. Alessandrini, K. L. McGowan, L. M. Bell, and K. N. Shaw Serotype Prevalence of Occult Pneumococcal Bacteremia Pediatrics, August 1, 2001; 108 (2): e23 - e23. [Abstract] [Full Text] [PDF]

				J. W. Gobel;, M. Rennels, J. Abramson, and J. Modlin The Rotavirus Vaccine Story Pediatrics, July 1, 2001; 108(1): 220 - 220. [Full Text]

				Committee on Infectious Diseases Recommended Childhood Immunization Schedule{---}United States, January-December 2001 Pediatrics, January 1, 2001; 107(1): 202 - 204. [Full Text]

				Recommendations for Use of Pneumococcal Conjugate Vaccine Journal Watch (General), September 19, 2000; 2000(919): 3 - 3. [Full Text]

				Committee on Infectious Diseases Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis Pediatrics, August 1, 2000; 106(2): 362 - 366. [Abstract] [Full Text]

	Home | My Pediatrics | Journal Information | Current Issue | Past Issues | Subscriptions & Services | Contact Us Click here for faster international access © 2000 American Academy of Pediatrics. All rights reserved.